Ellipses Pharma and SunRock Biopharma Enter Into a Licensing Agreement for a First-in-class Bifunctional HER3:TRAIL Fusion Protein

Ellipses Pharma granted exclusive global rights to develop and commercialise SRB22, in solid tumours SunRock Biopharma S.L. ("SunRock"), a biopharmaceutical company that is developing a portfolio

Related Keywords

London ,City Of ,United Kingdom ,Sunrock Biopharma ,Kostenloser Wertpapierhandel ,Rajan Jethwa ,Juan Buela ,Suzanne Wood ,Laureano Sim ,Ellipses Pharma ,Galicia Innova Tech Fund ,Ellipses Pharma Limited ,Ellipses Pharma Ltd ,Pharma Ltd ,Ellipses ,Dharma ,Gunrock ,Iopharma ,Winter ,Into ,Icensing ,Agreement ,First ,Glass ,Bifunctional ,Her3 ,Trail ,Fusion ,Protein ,